Stock 4588 ONCOLYS BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Oncolys BioPharma Inc.

Equities

4588

JP3202170001

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 07:00:00 02/05/2024 BST 		5-day change 1st Jan Change
706 JPY -0.56% Intraday chart for Oncolys BioPharma Inc. +2.92% +24.51%
02-09 Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-07 Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan CI

Business Summary

Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Number of employees: 40

Sales per Business

JPY in Million2022Weight2023Weight Delta
Drug Discovery
100.0 %
976 100.0 % 63 100.0 % -93.54%

Sales per region

JPY in Million2022Weight2023Weight Delta
Japan
55.5 %
950 97.4 % 35 55.5 % -96.32%
United States
44.5 %
26 2.6 % 28 44.5 % +8.72%

Managers

Managers TitleAgeSince
Yasuo Urata FOU
 Founder 68 17/03/04
Kohei Hata DFI
 Director of Finance/CFO - 31/12/18
Yasunari Kashihara BRD
 Director/Board Member 58 30/11/07
Katsufusa Tachiya AUD
 Comptroller/Controller/Auditor 73 30/06/11

Members of the board

Members of the board TitleAgeSince
Yasuo Urata FOU
 Founder 68 17/03/04
Naoko Iino BRD
 Director/Board Member 63 28/02/23
Yasunari Kashihara BRD
 Director/Board Member 58 30/11/07
Yasushi Saito BRD
 Director/Board Member - 28/02/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 20,961,600 18,715,362 ( 89.28 %) 88,738 ( 0.4233 %) 89.28 %

Shareholders

NameEquities%Valuation
ASTELLAS PHARMA INC.
3.585 %
727,200 3.585 % 4 M ¥
Yasuo Urata
2.450 %
496,900 2.450 % 3 M ¥
CHUGAI PHARMACEUTICAL CO., LTD
2.251 %
456,600 2.251 % 2 M ¥
Hitoshi Nakanishi
0.9515 %
193,000 0.9515 % 1 M ¥
ASAHI INTECC CO., LTD.
0.5847 %
118,600 0.5847 % 618 291 ¥
Yasunari Kashihara
0.5670 %
115,000 0.5670 % 599 524 ¥
ONCOLYS BIOPHARMA INC.
0.4053 %
82,200 0.4053 % 428 529 ¥
Keiji Yoshimura
0.0887 %
18,000 0.0887 % 93 839 ¥
SBI Asset Management Co., Ltd.
0.004432 %
899 0.004432 % 4 687 ¥
Simplex Asset Management Co., Ltd.
0.000000 %
0 0.000000 % - ¥

Holdings

NameEquities%Valuation
ONCOLYS BIOPHARMA INC.
0.41%
 82,200 0.41% 428,529 $

Company contact information

Oncolys BioPharma, Inc.

Toranomon Towers Office 4-1-28 Toranomon

105-0001, Tokyo

+

http://www.oncolys.com
address Oncolys BioPharma Inc.(4588)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ONCOLYS BIOPHARMA INC. Stock Oncolys BioPharma Inc.
+24.51% 95.81M
CSL LIMITED Stock CSL Limited
-3.79% 87.06B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.45% 40.25B
BIOGEN INC. Stock Biogen Inc.
-15.94% 31.09B
UCB Stock UCB
+52.66% 24.74B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.50% 15.91B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-14.38% 11.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.73B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4588 Stock
  4. Company Oncolys BioPharma Inc.